Technology Offers

Therapeutics

Recombinant human transglutaminase 1 encapsulated into liposomes for treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis

On 7 June 2013 orphan designation was granted by the European Commission for recombinant human transglutaminase 1 encapsulated into liposomes for the treatment of transglutaminase 1-deficient autosomal recessive congenital ichthyosis. EMA website

TG1-Liposomes

 

A novel approach to develop anti-metastatic drugs based on inhibition of Ena/VASP EVH1 domains

Anti-metastatic drugs

 

 

Research Tools / Protein Engineering 

KCNQ4 and KCNQ5 ion channels for the identification of selective channel function modulators  

Ion channels

 

Volume-regulated anion channel VRAC as a target in drug discovery

VRAC

 

Novel TPH inhibitors for the treatment of serotonin-related diseases

TPH inhibitors

 

 

Disease models

ISG15 KO
Useful for studying antiviral responses
Ref: Mol Cell Biol Aug 2005, Vol 25(15) pp 6338-45 by Osiak et al. 

ISG15 KO

 

USP8 lox/lox
Useful for studying the roles of ubiquitin-dependent protein trafficking of membrane proteins
Ref: Mol Cell Biol Jul 2007, Vol 27, No. 13, pp 5029-39 by Niendorf et al.

 

 

Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10
13125 Berlin, Germany
+4930 94793 - 100 
+4930 94793 - 109 (Fax)
info(at)fmp-berlin.de